Akonni

The exclusive two-way licensing deal also allows Akonni to commercialize Righton's molecular diagnostic tests outside of China.

The grant was awarded under a program designed to help small businesses transition NIH-funded projects into the commercialization stage.

The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.

The funding will be used in part to prepare an FDA submission for a clinical IVD pharmacogenomic test for its TruDx 2000 microarray platform.

An RT-qPCR-based assay of antigen-stimulated blood is a possible next-gen approach for latent TB detection, a Cepheid executive noted in an accompanying commentary.

Title: Biochip
Patent Number: 8,753,874
Filed: Dec. 15, 2003
Lead Inventor: Walter Gumbrecht, Siemens

Harvard University and Akonni Biosystems have teamed up to develop and test an amplification array-based diagnostic for multi-drug-resistant and extreme-drug-resistant tuberculosis.

NEW YORK (GenomeWeb News) – Harvard Medical School and Columbia University have both received grants from the National Institute of Allergy and Infectious Diseases, totaling $12.3 million this year, to create translational research centers to develop molecular diagnostics technologies.

Biological Dynamics has been awarded US Patent No. 8,603,791, "Nucleic acid sample preparation."

Korean technology and test developer Seegene this week said that it has developed a new, real-time microarray platform that it claims eliminates the "burdensome, time-consuming" steps associated with current array technologies, and is "highly applicable" to point-of-care testing.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.